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Titanium dioxide (TiO2) nanoparticles are one of the most highly manufactured
nanomaterials in the world with applications in copious industrial and consumer products.
The liver is a major accumulation site for many nanoparticles, including TiO2, directly
through intentional ingestion or indirectly through increased environmental contamination
and unintentional ingestion via water, food or animals. Growing concerns over the current
usage of TiO2 coupled with the lack of mechanistic understanding of its potential health
risk is the motivation for this study. Here we determined the toxic effect of three different
TiO2 nanoparticles (commercially available rutile, anatase and P25) on primary rat
hepatocytes. Specifically, we evaluated events related to hepatic functions and
mitochondrial dynamics: (1) urea and albumin synthesis using colorimetric and ELISA
assays, respectively; (2) redox signaling mechanisms by measuring ROS production; (3)
OPA1 and Mfn-1 expression that mediates the mitochondria dynamics by PCR; and (4)
mitochondrial morphology by MitoTracker Green FM staining. All three TiO2
nanoparticles induced a significant loss in hepatic functions even at concentrations as low
as 20 µg/ml with commercially used P25 causing maximum damage. TiO2 nanoparticles

induced a strong oxidative stress in primary hepatocytes.TiO2 nanoparticles exposure also
resulted in morphological changes in mitochondria and significant loss in the fusion
process, thus impairing the mitochondrial dynamics. Although this study demonstrated that
TiO2 nanoparticles exposure resulted in significant damage in primary hepatocytes, more
in vitro and in vivo studies are required to determine the complete toxicological mechanism
on primary hepatocytes and subsequently liver function.
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Chapter 1 Thesis Introduction and Background
1.1 Nanotechnology and Titanium Dioxide (TiO2) Nanoparticles:
In the last two decades, Nanotechnology has revolutionized industries as diverse as
engineering, health science and information technology. 1 Novel materials with valuable
nanoscale properties are being discovered and engineered on large scale to meet with the
increasing demands in the fields of application. Engineered nanoparticles form a major
fraction of man-made nanomaterials that is increasing rapidly, escalating in both
development and commercial implementation in applications such as drug delivery
systems, antibacterial materials, cosmetics, biosensors, tissue engineering and electronics,
yielding over thousands of consumer-based products already available in the market.2
Among engineered nanoparticles, titanium dioxide (TiO2) ranks as one of the most highly
manufactured and consumed type, from the perspective of both consumer products and
research applications.

2 3 4

These metal nanoparticles are commercially synthesized in

rutile and anatase crystal forms. Nanoparticles of TiO2 possess significantly different
physicochemical properties, compared to the bulk phase, like strong catalytic activity, high
refractive index, stability and photo sensitivity. 2 These unique properties render the TiO2
nanoparticles very versatile and find them applications in a wide spectrum of industries
ranging from water treatment, cosmetics, paint sunscreens, air cleaning, foods,
sterilization, implants, to pharmaceuticals. 4 5 6 7 8 9 10

2
1.2 Nanotoxicology:
Despite the growing popularity, the largely different repertoire of physicochemical
properties of nanomaterials gives rise to concerns over their bioactivity profile.
Nanoparticles are exploited for properties such as small size, increases surface area, higher
reactivity, aggregation potential, and different optical and electrical properties, as
compared to their bulk phase counterparts. These differences influence the nature of
interaction of nanomaterials with biological and ecological systems that were not a concern
with the bulk material. For example, small particles can enter cells with ease and interact
with the intracellular macromolecules.

11

They can escape conventional phagocytic

responses and gain access to circulation and nervous system.

1

Inhalation of nano-

dimensioned material can gain it easy access to respiratory system and the brain. 2 Apart
from the inherent material properties, the synthesis technique, the route of exposure and
level of exposure (acute, chronic or sub-chronic) understandably play a crucial role in their
nature of interaction with biological systems.
In the event of these concerns, the US Environmental Protection Agency (EPA) and other
central environmental bodies have expressed their concerns about potential toxicity of
nanoparticles and are considering measures to limit the use in commercial products and
increase the government regulations .12
1.3 Titanium Dioxide Nanoparticle Toxicity:
Metal nanoparticles such as Titanium Dioxide have been used in a variety of common
consumer products such as food, cosmetics, air/water purifier, medicines, toothpastes and

3
sunscreens. 3 Due to the abundance of commonly found products that contain TiO2, there
is a high chance of repeated exposure to these particles.
Various routes of exposure that can lead to the systemic availability of these nanoparticles
and the most common ones are oral, subcutaneous, dermal, intravenous and lastly,
respiratory. Respiratory exposure risks are particularly elevated in the form of occupational
hazard. Previous reports show that over 150 different cosmetic products can lead to long
term dermal exposure of titanium dioxide nanoparticles (Fig. 1). The whitening properties
of TiO2 nanoparticles renders them useful as a food colorant. A recent study demonstrates
the various common food products that have these nanoparticles in them (Fig. 2), along
with the likely daily exposure to humans of various age groups (Fig. 3). 3 Repeated use of
TiO2 containing nanoparticles can lead to chronic level exposure and accumulation in
various organs.

Figure 1. Quantification of Titanium Dioxide Nanoparticles in Various Cosmetic Products

Published in: Alex Weir; Paul Westerhoff; Lars Fabricius; Kiril Hristovski; Natalie von Goetz; Environ. Sci.
Technol. 2012, 46, 2242-2250. Copyright © 2012 American Chemical Society
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Figure 2. Quantification of Titanium Dioxide Nanoparticles in Various Food Product Groups
Published in: Alex Weir; Paul Westerhoff; Lars Fabricius; Kiril Hristovski; Natalie von Goetz;
Environ. Sci. Technol. 2012, 46, 2242-2250. Copyright © 2012 American Chemical Society

Figure 3Consumption of TiO2 according to age group

Published in: Alex Weir; Paul Westerhoff; Lars Fabricius; Kiril Hristovski; Natalie von Goetz;
Environ. Sci. Technol. 2012, 46, 2242-2250. Copyright © 2012 American Chemical Society
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Several research groups have studied the toxicological behavior of TiO2 nanoparticles
using in vivo and in vitro models. The effects elicited by these particles on the respiratory
system are most elaborately studied. 13 14 15 Multiple studies on animal models have shown
that exposure to TiO2 nanoparticles has led to detrimental responses like Reactive Oxygen
Species (ROS) generation, increased immune response, triggering of inflammation and
accumulation in the system. Multiple cases of in vitro studies on various different sources
of cells have also shown phenomena of apoptosis and genotoxicity, upon exposure of these
nanoparticles.
1.4 The liver and Nanoparticle toxicity:

The liver is a multicellular organ that performs numerous vital metabolic, synthetic and
clearance-related functions in mammals. Hepatocytes account for approximately 80% of
the liver mass and perform essential metabolic functions in the normal and diseased liver.
Studies demonstrate that the liver is a major accumulation site for many nanoparticles,
directly through intentional ingestion or indirectly through nanoparticle dissolution from
food containers or secondary ingestion of inhaled particles.11, 16-18 Additionally, increased
environmental contamination and unintentional ingestion via water, food or animals may
also result in further contact and subsequent accumulation of nanoparticles in the liver.11,
19, 20

Being the primary site for exposure to numerous nanoparticles renders the liver a high

risk-site for damage from these foreign materials.
Studies on the bio-distribution of TiO2 nanoparticles have depicted the liver as one of the
principal sites in the body for accumulation.16, 21 The concern about adverse health effects
of low-level exposure to TiO2 is imperative to address, particularly study regarding TiO2

6
exposure leading to liver degeneration by impairing mitochondrial bioenergetics. As a
means to address these concerns and to establish the toxicological profile of TiO2
nanoparticles, various groups have studied the effects elicited by these particles on different
biological systems, both in vitro and in vivo.13, 22 Few studies provide evidence of impaired
mitochondrial bioenergetics and apoptotic cell degeneration after low-level exposure to
TiO2. 23, 24 There is a plethora of published literature on acute TiO2 toxicity, however, the
effect of TiO2 exposure on the hepatocyte mitochondria and its implications on liver remain
to be investigated.

7

Thesis Overview:
This thesis focuses on identifying and characterizing titanium dioxide nanoparticles that
are commonly used in commercial applications and investigating the perturbations in liver
behavior and mitochondrial characteristics caused by exposure to these TiO2 nanoparticles,
in order to broaden our understanding on the molecular mechanisms of liver dysfunction
induced by these highly utilized nanoparticles. Chapter 2 describes the preparation of
nanoparticles suspensions and characterization. Chapter 3 focuses on developing primary
rat hepatocytes as our model liver system to investigate the concentration and type
dependent toxic effects of TiO2 nanoparticles on hepatic functions. Chapter 4 describes our
findings about the mechanistic aspects that could trigger the changes observed in primary
hepatocytes, upon treatment with TiO2 nanoparticles. Chapter 5 contains the overall
summary of the results obtained and potential future directions that will aid in the deeper
understanding of the effects of TiO2 nanoparticles on the liver cells.
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Chapter 2 Characterization of Titanium Dioxide Nanoparticles
2.1 Introduction
2.1.1 Importance of Nanoparticle Characterization:
Nanoparticle characterization plays an important role in interpreting and comparing the
toxicological effects elicited by the different types of TiO2 on the specific biological
system. TiO2 nanoparticles are typically available in the anatase or rutile crystal forms.
Parameters such as particle size, crystal phase and aggregation potential influence their
bio-activity. 25 Different crystal forms of the nanoparticle have previously been shown to
elicit different toxicological responses. Anatase crystal has been shown to possess higher
reactivity of the two crystal forms.

26

The mechanism of toxicity elicited by the particles

are also different. Previous studies show that anatase crystals can lead to cell necrosis and
membrane leakage. Some studies also show that generation of Reactive Oxygen Species
(ROS) occurs, whereas a few groups observe otherwise.

27 28

On the contrary, rutile

particles were shown to initiate apoptosis through ROS formation.

28

Variations with

respect to initial particle size have also been observed by several groups. 26 These different
results demonstrate the importance of characterizing the physicochemical parameters of
the nanoparticle type in question, in order to fully understand and profile the toxicological
behavior elicited by it. Fig. 4 is a cartoon representation of rutile and anatase crystal forms
of TiO2 nanoparticles.

9

Rutile

Anatase

Figure 4. Schematic Representation of Rutile and Anatase Crystal shapes of Titanium Dioxide
Nanoparticles

2.1.2 Nanoparticle Selection for the Study:

We chose three commercially available forms of TiO2 nanoparticles (anatase, rutile and
Degussa P25) for our study to determine their toxicological effects on primary rat
hepatocytes. These particles were selected due to their higher potential of human exposure
through abundance in consumer products and availability in water sources. Our study
focused on investigating the crystal phase dependent effects of titanium dioxide
nanoparticles on the cells. To keep crystal phase as the only variable, we chose pure rutile
and pure anatase samples of same particle size of 50 nm. Degussa P25, a commercially
available TiO2 nanoparticle type is a mixture of both anatase and rutile. These three TiO2
nanoparticles are referred to as anatase, rutile and P25 in the thesis hereon.
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2.2 Materials and Methods
2.2.1 Preparation of TiO2 nanoparticle suspensions
Degussa P25 was obtained from Sigma Aldrich, St. Louis, MO. Pure rutile 50nm, and pure
anatase 50nm were purchased from MK Nano, Mississauga, Ontario, Canada. The
nanoparticles were UV sterilized and stock suspensions were made in sterile Phosphate
Buffer Saline (PBS) at pH 7.4, mixed for 2 minutes, sonicated [FS30D Fisher Scientific]
for 30 min and stored in dark at 4 ºC until use.
2.2.2 Dynamic Light Scattering
TiO2 Nanoparticle size and zeta potential were measured using a NanoBrook ZetaPALS
zeta potential and dynamic light scattering instrument [Brookhaven instrument, Holtsville,
NY]. Desired concentrations of nanoparticle suspensions were prepared by dilution with
Hepatocyte culture medium (described in Chapter 3). Mean hydrodynamic diameter was
measured at a scattering angle of 90°, and the Zeta potential was calculated from Mobility
measurements by using the Smoluchowski model. All measurements were performed at 25
ºC at a pH of 7.4.
2.2.3 Transmission Electron Microscopy

Stable suspensions of the different nanoparticles was prepared in DI water using sonication.
The samples were prepared for imaging by sequential drying steps on copper grids [Ted
Pella, Inc., CA] that were coated with carbon. Hitachi H7500 TEM was used for analyzing
the samples.

11
2.3 Results
2.3.1 Aggregation and Surface Charge of the Nanoparticles
TiO2 nanoparticles aggregates in aqueous hepatocyte media were characterized using DLS.
The purity of the starting nanoparticles was over 95%. To measure the hydrodynamic
diameter of the aggregates and their resultant zeta potential, working concentration of
nanoparticles suspension were prepared in hepatocyte media in the identical manner in
which they are prepared for the cell culture studies. As shown in Table. 1, P25, anatase,
and rutile nanoparticles aggregated to average diameter of approximately 800nm, 700nm,
and 380nm, respectively. The aggregate hydrodynamic diameter did not vary significantly
with the varying concentration of the nanoparticles, in all three sample types (Fig. 5). Zeta
potential were also measured for the three TiO2 nanoparticles (Table. 1). The zeta potential
values did not change significantly in the three forms of the nanoparticles and in all three
concentrations.

2.3.2 Particle Size and Shape of the Nanoparticles
TEM was used to define the individual crystal shapes and sizes of the different TiO2
nanoparticles (Fig. 6). Anatase TiO2 nanoparticles displayed the characteristic spherical
crystal structure, with each particle size around 50nm and rutile nanoparticles displayed a
typical rod-like crystal structure. P25, which is a 3:1 mixture of anatase and rutile, had
crystals characteristic of both anatase and rutile. These results were in agreement with the
manufacturer’s specifications and previous reports on the characterization of the shape of
the nanoparticles.21, 25, 26
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Table 1. Characterization of TiO2 nanoparticles aggregates forming in hepatocyte culture
medium using Dynamic Light Scattering (DLS) at 37 ºC and pH of 7.4.

Figure 5. Comparison of Hydrodynamic Diameters of Nanoparticles in Different Concentrations

13

A

B

C

Figure 6. Transmission Electron Microscopy images to characterize the crystal shape of the TiO2
NPs as seen in DI water; (a) P25, (b) Anatase, 50 nm particle size and (c) Rutile , 50 nm particle
size, scale = 50 nm
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2.4 Discussion
Nanoparticle characterization plays a vital role in interpreting and comparing the
toxicological effects elicited by the different types of TiO2 on the specific biological
system. We chose three commercially available forms of TiO2 nanoparticles (anatase, rutile
and P25) for our study to determine their toxicological effects on primary rat hepatocytes.
Our TEM results indicate that the crystal structure of anatase was spherical, rutile was rod
shaped and P25 had a mixture of both the crystal structures. (Fig. 6) TiO2 nanoparticles
have the tendency to form aggregates in aqueous media that have high ionic strength. To
compare the level of aggregation of the TiO2 nanoparticles in physiologically relevant
conditions including the presence of proteins and divalent ions, we studied the aggregation
nature of the TiO2 nanoparticles in serum containing hepatocyte culture media. As seen in
Table. 1, the aggregation did not vary significantly with the concentration of the
nanoparticle suspension, within the same type. For the variation of the aggregate sizes
between the different nanoparticles, the type of crystal structure of the particles (anatase vs
rutile) and the relative composition of the three forms of nanoparticles might attribute to
the observed variations in their aggregation sizes.
In agreement with the aggregation in the physiologically relevant media, the zeta potential
for all three TiO2 crystalline forms, regardless of concentration, was measured to be within
the realm of colloidal instability. Our extensive characterization provides us with valuable
information about the physicochemical properties of the different type of particles the cells
are interacting with when they are exposed to TiO2.
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2.4 Conclusion
We were able to characterize the individual particle shape and size using TEM and
observed a typical crystal shape of rod-like in rutile and spherical in anatase, consistent
with the previous reports on similar characterization. With the DLS study, we were able to
characterize the hydrodynamic diameter and zeta potential of the different titanium dioxide
nanoparticles in hepatocyte medium. These characterizations will prove useful in
correlating our observations with the inherent physicochemical behavior of the particles.

16

Chapter 3 Effect of Titanium Dioxide Nanoparticles on Primary
Hepatocyte Viability and Functions
3.1 Introduction

3.1.1 TiO2 Nanoparticles mediated Toxicity to The Liver
Exposure routes such as respiratory, oral, intravenous and dermal have scope for systemic
access to foreign particles. Previous reports on the bio-distribution of TiO2 nanoparticles
suggest high likelihood for the particles to reach the liver and accumulate.

22 29

Study by

Fabian et al demonstrates that traces of nanoparticles were found in the liver 28 days after
intravenous exposure to anatase and rutile TiO2 nanoparticles.

30

Cui et al showed that

prolonged intra-gastric instillation of TiO2 Nanoparticles causes NF kB mediated
inflammation, followed by apoptosis in the liver of mice models.

31

Some recent in vitro studies have also investigated the toxicity of these metal nanoparticles
on the liver cells. Shi et al showed that human L02 hepatocytes displayed increased
oxidative stress due to ultrafine TiO2 nanoparticle exposure. 32 Similar results of oxidative
stress were observed in BRL 3A rat liver cell line. 33
Limited number of studies have been carried out in order to explore the mechanistic aspects
of TiO2 Nanoparticles on hepatocytes. Studies carried out on animal models have the
limitation of being complex and it is challenging to deduce the observations to a particular
cell type without accounting for the exogenous factors. Similarly, use of hepatic cell lines
pose the disadvantage of potential deviation from the actual liver biology owing to the
transformations cell lines undergo.
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3.1.2 Primary Hepatocytes as in vitro Liver Models
Hepatocytes are the most important cell type of the liver and perform numerous vital
metabolic, storage and clearance related functions.

34

Primary hepatocytes retain a

considerable fraction of their complex functions when cultured in suitable conditions in
vitro. Prolonged culture of hepatocytes leads to loss in the differentiated phenotype and
this event precedes cell death. To understand the cytotoxicity of nanoparticles, along with
general end point assays such as quantification of viability and morphology, studying the
hepatocyte specific phenotypic markers is essential. Hepatocyte specific functions like
synthesis of albumin and urea are gold standard markers for characterizing the phenotypic
stability of the cells. 34 We investigated how these functions were affected by the exposure.
To be able to study cellular events prior to cell death, as a preliminary step before studying
the cellular markers, we determined the cytotoxicity of the different types of TiO 2
Nanoparticles on primary hepatocytes in order to obtain the lethal concentration value
(LC50).
3.2 Materials and Methods
3.2.1 Isolation of Primary Hepatocytes
All animal procedures were carried out in accordance with the guidelines from IACUC of
University of Nebraska-Lincoln. Excision of the liver followed by isolation of hepatocytes
was performed as per the protocol of P.O Seglen and R.Blomhoff

35

with slight

modifications. Sprague Dawley rats weighing about 160-200g were subjected to
anesthetic-conditions in a desiccator chamber saturated with 30% isoflurane solution. The
rats were kept in the chamber till the full effect of anesthesia was confirmed, which is
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limpness of the body and deep respiration. The animal was moved to the surgery table and
a syringe tube with isoflurane was secured on the snout for assuring prolonged
unconsciousness. With bandage scissors and forceps, the entire abdominal cavity was
exposed and vena porta was located. A strand of surgical thread was drawn beneath the
vena port and an overhand knot was tied. Vein was cannulated with Insyte Autoguard
catheter (18GA, 1.3x300mm, BD Biosciences). The needle was retracted and oxygenated
Tris Buffer Saline (TBS) was supplied through the catheter at a flow rate of about
20mL/min and was continued till the liver turned loam colored. Liver was excised out of
the abdominal cavity by cutting around all the tissues that attach it to the body. Liver was
placed on a sieved funnel and buffer was allowed to continually flush the blood away.
Digestion of the liver by collagenase digestion followed next. Collagenase solution of
strength about 10 mg per 100 grams of rat’s weight was prepared in 60 mL of Calcium
containing buffer. The TBS flushing was brought to an end and collagenase was pumped
in through a closed circuit. After about 15 minutes, the liver was transferred to a sterile
dish containing buffer 1 and Glisson’s capsule and extra tissues, if any, were peeled away.
The liver was shook in the buffer to detach all the hepatocytes in the liver matrix. And the
buffer loaded with cells was filtered through 100 µm followed by 30um to get a purer
population of hepatocytes. The filtrate was centrifuged with buffer 3 and 150xg for 3
minutes and the process was repeated till the supernatant was clear and the pellet intact.
The viability of hepatocytes was determined using trypan blue exclusion method, was also
confirmed using percoll gradient. Viability of 85% and above was considered threshold for
continuing with culture.
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3.2.2 Culture and Treatment of Primary Hepatocytes
Before seeding, tissue culture plate surfaces were coated with 100µg/ml rat tail collagen
type I solution prepared in 0.02 N acetic acid for 1 hour at 37 ºC, washed and stored at 4
ºC till use. Cells were seeded at a density of 100,000/cm2 on the collagen coated plates.
Nanoparticle suspensions in the desired concentrations were prepared in the culture media
and added to the cells.
Hepatocyte Culture Medium: Culture media was made with high glucose DMEM
supplemented with 10% FBS, 0.5 U/ml insulin, 20 ng/ml epidermal growth factor (EGF),
7 ng/ml glucagon, 7.5 mg/ml hydrocortisone, and 1% penicillin-streptomycin. All the
reagents were obtained from Sigma-Aldrich.
3.2.3 Cytotoxicity Assay to Determine LC50
The cytotoxicity of nanoparticles was assessed by MTT assay [3-(4,5-dimethyldiazol-2yl)2,5 diphenyl Tetrazolium Bromide] [Life Technologies, NY] which quantitatively
evaluates the mitochondrial conversion of the MTT salt into purple formazan crystals..
Nanoparticle solution was removed and 0.5 mg/ml MTT working solution in DMEM was
incubated on live cells at 37 ºC for 2.5 hours. After incubation the working solution was
removed and lysis buffer (0.1 N HCl in Isopropanol) added. The lysis buffer was
transferred to a 96 well plate and absorbance values collected in an AD340 plate reader
[Beckman Coulter, Brea, CA] at corrected 570/620 nm. Relative absorbance was used as
the indicator for cell viability. Concentration range of 0 µg/ml to 1000 µg/ml for each
nanoparticle was used to generate the dose response curve. SigmaPlot software was used
to calculate LC50 value for each type of nanoparticle.

20
3.2.4 Scanning Electron Microscopy (SEM)
Nanoparticle size and shape were assessed and viewed under a scanning electron
microscope (SEM) [S-3000N, Hitachi Tokyo, Japan]. Cellular morphology and
nanoparticle distribution was visualized by SEM. The cells were rinsed with PBS and fixed
with 4% paraformaldehyde/PBS solution for 15 min. The paraformaldehyde solution was
removed, samples rinsed with PBS and dehydrated with ethanol solutions (from 20 to
100%). The sample was incubated for 15 min at room temperature in each solution. The
100% ethanol solution was removed with hexamethyl disilazane [Sigma Aldrich, USA]
and the sample was allowed to air-dry. The samples were then coated with gold-palladium
(Au-Pd) and analyzed under the SEM.
3.2.5 Live Dead Fluorescent Assay
Cell viability was assessed using a Live/Dead Viability/Cytotoxicity Kit [L-3224
Invitrogen, Grand Island, NY]. In short, Nanoparticle supernatant was removed and cells
were washed once with PBS and incubated at 37 ºC for 30 min with assay reagent (4 uM
EthD-1 and 2 µM Calcein in PBS) at 37 ºC. The cells were removed and washed 3 times
with PBS and viewed with an Axiovert 40 CFL [Zeiss, Germany] and X-Cite 120Q [Lumin
Dynamics, Mississauga, Ontario, Canada].
3.2.6 Urea Quantification Assay
Urea secretion by hepatocytes in culture medium was assessed every 24 hours using
Stanbio Urea Nitrogen (BUN) kit [Stanbio, Boerne, TX] using manufacturer’s protocol.
Briefly, the kit exploits the reaction between urea and diacetyl monoxime which results in
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a color change with an absorbance of 520 nm read on AD 340 plate spectrophotometer
[Beckman Coulter, Brea, CA].
3.2.7 Albumin Quantification ELISA
Albumin Secretion by hepatocytes into culture medium was measured every 24 hours using
Rat Albumin ELISA Quantitation Kit from Bethyl Laboratories, Inc [Montgomery, TX]
according to manufacturer’s instructions. In short, a 96 well plate was coated with a coating
antibody for 1 hour and blocked with BSA for 30 min. Standard/Sample was added to each
well and incubated for 1 hour. HRP detection antibody was incubated for 1 hour followed
by the addition of TMB Substrate solution which was developed in the dark for 15 min and
absorbance read on AD340 plate spectrophotometer [Beckman Coulter, Brea, CA] at 450
nm.
3.2.8 Cell Morphology Analysis:
Phase contrast images of primary hepatocytes cultured on the different substrates were
captured using an Inverted Microscope [Axiovert 40 CFL, Zeiss, Germany]. For
fluorescent viewing of the cell morphology, Calcein AM staining was used [Life
Technology, NY].
3.2.9 Statistical Analysis:
The difference between the various experimental groups was analyzed by a one-way
analysis of variance (ANOVA) using the statistical analysis feature embedded in SigmaPlot
Software using Tukey test. Q tests were employed to identify outliers in the data subsets.
For statistical analysis of all data, p<0.05 was used as the threshold for significance.
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3.3 Results
3.3.1 Cytotoxicity of TiO2 Nanoparticles on Primary Hepatocytes
We evaluated the cytotoxicity of three different TiO2 nanoparticles (P25, anatase and rutile)
that were selected due to their abundance in commercial products using MTT assay. A 72
h exposure to the three different TiO2 nanoparticles of varying concentration (0-1000
µg/ml) to primary hepatocytes established the LC50 value of the different particles. As seen
in Table. 2, the LC50 values of P25, anatase and rutile TiO2 nanoparticles were 74.13±9.72
µg/ml, 58.35±4.76 µg/ml, and 106.81±11.24 µg/ml, respectively. Fig. 7 represents the
dose response curves plotted using Sigma Plot for the different nanoparticles using nonlinear regression that were used to analyze the LC50 values. After determining the LC50
values, the concentrations of 20, 50 and 100 µg/ml were chosen for the rest of the studies
to enable studying the cellular phenomena at a sub-acute dosage range.

Table 2: Lethal Concentration (LC50) analysis of the different TiO2 nanoparticles treatment of
primary rat hepatocytes.
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Figure 7. Dose response curve to calculate LC50 using four parameter plots for the different
titanium dioxide nanoparticle treatment on primary hepatocytes
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To study the concentration dependent effect of TiO2 nanoparticles on primary hepatocyte
morphology, we observed the cellular characteristics using SEM (Fig. 8). After 72 h of
exposure to the three chosen concentrations of the nanoparticles, primary hepatocytes did
not exhibit a marked change in cellular morphology. For all three nanoparticles we
observed the smooth and spherical morphology of hepatocytes that was comparable to
untreated cells.

Figure 8. Scanning Electron Microscopy (SEM) images to visualize the morphology of primary
hepatocytes when treated with TiO2 nanoparticles after 72 h of exposure. Scale bar: 30 microns.
Yellow arrows point to primary hepatocytes
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3.3.3 TiO2 Nanoparticles and Primary Hepatocyte Cell Viability
To quantitatively determine the viability loss in hepatocytes after exposure to TiO2
nanoparticles, we performed MTT assay. Hepatocytes were treated in the chosen
concentrations (20, 50 and 100 µg/ml) of P25, anatase, and rutile for 72 h. The exposure
of hepatocytes to TiO2 nanoparticles showed a concentration and type dependent loss in
viability (Fig. 9). We normalized the viability of TiO2 nanoparticles treated hepatocytes
with respect to untreated cells. In P25 treated samples, 91% cells were viable when exposed
to 20 µg/ml concentration which decreased to 75% at 100 µg/ml concentration. Similarly
in hepatocytes exposed to anatase nanoparticles, the cell viability significantly decreased
from 92% in the 20 µg/ml concentration to 66% in 100 µg/ml. However, all three
concentrations of rutile did not affect the cell viability and had the highest percentage of
viable cells even at a concentration of 100 µg/ml.
In addition, to study the effect of nanoparticle treatment after a prolonged duration, we
performed Live/Dead Fluorescent cell staining as seen in Fig. 10. These results also suggest
similar phenomenon. Anatase and P25 showed a greater loss in viability as compared to
rutile and the effect was observed to be concentration dependent.
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Figure 9. MTT assay to quantify primary hepatocyte viability after treatment with different TiO2
nanoparticles at 20, 50 and 100 µg/ml after 72 h of exposure normalized to the untreated
hepatocytes. * p value < 0.001
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Figure 10. Live/Dead dual fluorescent staining of primary hepatocytes when treated with
titanium dioxide nanoparticles on Day 7 in culture. Calcein FM stains the live cells green and
Ethidium Bromide stains the dead cells red. Scale bar: 100 microns.
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3.3.3 TiO2 Nanoparticles and Primary Hepatocyte Specific Functions
3.3.3.1 Urea Synthesis
We studied the effect of prolonged exposure of hepatocytes to three chosen concentrations
(20 µg/ml, 50 µg/ml, 100 µg/ml) and types of TiO 2 nanoparticles (P25, anatase, rutile) on
two chief hepatic functions; urea synthesis and albumin synthesis. We quantified the
amount of urea synthesized by hepatocytes upon treatment with TiO2 nanoparticles, using
a colorimetric assay (Fig. 11 and Fig. 12). Fig.11 illustrates the urea production of primary
hepatocytes after 72 h of exposure to different TiO2 nanoparticles. We normalized the value
of urea and albumin synthesis of the treatment groups with respect to the untreated cells.
We observed significant concentration and type dependent loss in urea synthesis. The
exposure of hepatocytes to 20 µg/ml, 50 µg/ml, and 100 µg/ml of P25 resulted in 29%,
42%, and 57% loss of urea production, respectively. The exposure of hepatocytes to 20, 50
and 100 µg/ml of anatase resulted in 8%, 20%, and 42% loss of urea production,
respectively. The exposure of hepatocytes to rutile resulted in negligible loss of urea
production in all three concentrations compared to untreated cells. The comprehensive
quantification of urea synthesis for a week demonstrated similar trend when exposed to the
different concentrations of the TiO2 nanoparticles Fig. 12.
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Figure 11. Characterizing the effect of the different TiO2 nanoparticles treatment on primary
hepatocytes specific functions; Quantification of urea synthesized primary hepatocytes after 72 h
of exposure normalized to the untreated cells * p value < 0.001,
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Figure 12. Quantification of urea synthesized primary hepatocytes from day 1 to day 7 in culture
when treated with the different TiO2 nanoparticles. All the data points are normalized to
untreated hepatocytes
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3.3.3.2 Albumin Synthesis
We further quantified the amount of albumin synthesized using sandwich ELISA
technique. Fig. 13 illustrates the albumin synthesis of primary hepatocytes after 72 h of
exposure to different TiO2 nanoparticles. We observed significant concentration and type
dependent loss in albumin synthesis comparable to our data on urea production. The
exposure of hepatocytes to 20, 50, and 100 µg/ml of P25 resulted in 27%, 41%, and 60%
loss of albumin production, respectively. The exposure of hepatocytes to 20, 50, and 100
µg/ml of anatase resulted in 10%, 20%, and 35% loss of albumin production, respectively.
Akin to the urea production, the exposure of hepatocytes to rutile resulted in decreased
albumin production in all three concentrations compared to untreated cells. The
comprehensive quantification of albumin synthesis for a week demonstrated similar trend
when exposed to the different concentrations of the TiO2 nanoparticles Fig. 14.
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Figure 13. Characterizing the effect of the different TiO2 nanoparticles treatment on primary
hepatocytes specific functions; Quantification of albumin synthesized primary hepatocytes after
72 h of exposure normalized to the untreated cells * p value < 0.001, # p value 0.01
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Figure 14. Quantification of albumin synthesized primary hepatocytes from day 1 to day 7 in
culture when treated with the different TiO2 nanoparticles. All the data points are normalized to
untreated hepatocytes.

3.4 Discussion
Following the nanoparticle characterization, we studied the cytotoxicity of the different
types of nanoparticles using MTT assay (Table. 2 and Fig. 7). Our observations are in
agreement with some reports36, 37 and in disagreement with others38 on the cytotoxicity of
TiO2 nanoparticles. This discrepancy may be due to several reasons including the technique

34
employed in evaluating cellular changes, such as membrane permeability (live/dead
fluorescent staining and trypan blue assays) versus mitochondrial function (3-(4,5dimethylthiazole-2-yl)-2,5-biphenyl tetrazolium bromide or MTT assay)
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. Our result

indicates that pure anatase and P25 nanoparticles are more cytotoxic compared to rutile
nanoparticles. This trend is consistent with previous reports comparing the anatase and
rutile TiO2 nanoparticles.26 This result also provides us with the range of concentration
that needs to be addressed to enable complete mechanistic understanding of TiO2
nanoparticles mediated toxicity in liver cells. These concentrations are in the relevant subacute range, as compared to previous studies that have been carried out focusing on effect
of TiO2 nanoparticle exposure on liver

16, 33, 40, 41

Numerous in vitro studies studying the

toxicity of TiO2 nanoparticle have consistently used high concentrations of the
nanoparticles, thus limiting these studies to probe mechanistic studies beyond toxicity of
the nanoparticles26,

42, 43

The purpose of our study is to further investigate how TiO2

nanoparticles exposure affect primary hepatocytes, with a particular focus on changes in
cellular phenotype and mechanisms that mediate these changes. As a result we specifically
chose three concentrations of TiO2 nanoparticles for all the subsequent mechanistic studies
(20 µg/ml, 50 µg/ml, 100 µg/ml) with 72 h exposures that is reflective of the LC 50 data.
These concentrations fall in the sub-lethal range, thereby permitting us to investigate
crucial early cellular events, which will yield a better mechanistic understanding of the
intrinsic factors mediating nanoparticle induced toxicity.
To determine the effect of the different nanoparticles in the chosen concentration on
primary hepatocyte morphology, we used SEM imaging. As seen from Fig. 8, the cells did
not display a marked change in morphology. Hepatocytes did not exhibit significant change
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in aggregate formation or loss in attachment from the culture substrate. Typically cells that
are necrotic have distinct surface features in the form of loss of membrane integrity and
presence of surface lesions. However, such features were missing in hepatocytes exposed
to all three TiO2 nanoparticles.
Subsequently, we observed compromise in cell viability through MTT assay which was
most pronounced in P25 and anatase. The loss in viability was also directly dependent on
the concentration of treatment. The loss in viability was not significantly pronounced in
rutile treated samples (Fig. 9).These results indicate that there is a concentration and type
dependent effect on primary hepatocytes when exposed to TiO2 nanoparticles. Upon
extending the treatment time, we also observed drastic loss in cell viability when
hepatocytes were exposed to P25 and anatase for one week while exposure to rutile did not
show significant change in viability (Fig. 10). This difference in the cell behavior reflects
on potentially different modes of actions from the different TiO2 nanoparticles on the
hepatic biology.
We examined the effect of TiO2 nanoparticle treatment on primary hepatocyte specific
functions by quantifying urea and albumin synthesis (Fig.11 to Fig. 14). Hepatocyte
mediated urea production is an indicator of intact nitrogen metabolism and detoxification
and albumin synthesis is a widely accepted marker of hepatocyte synthetic function. We
observed significant loss in urea and albumin synthesis function of hepatocytes, which was
both concentration and type dependent. Exposure to rutile, in line with earlier observations,
resulted in the least loss in both urea and albumin synthesis.
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Animal studies have shown that damage does occur to the liver when exposed to TiO 2
nanoparticles, however, it is challenging to deduce the effect of nanoparticles on a
particular cell type using an in vivo study. Limited number of in vitro studies has been
carried out to understand the direct effect of TiO2 nanoparticles on liver using primary
hepatocytes.33, 40, 44, 45 A major weakness of existing literature about the in vitro effects of
nanoparticles is that the in vivo dosimetry and biokinetics are largely ignored, i.e., effects,
if observed, are at high concentrations.46, 47 There is a deficiency in a conclusive result for
the direct effect of these nanoparticles on hepatocytes functions when exposed to lower
concentrations of nanoparticles. These results demonstrate that even though the
hepatocytes have high viability at 72 h, the exposure to P25 and anatase results in
significant damage to hepatic functions. The most critical observation is the exposure to
100 µg/ml of commercially used P25 TiO2 nanoparticles for 72 h, though has 77% viable
cells, results in 60% loss in hepatic functions. We hypothesize that exposure to TiO 2
nanoparticles causes significant stress and damage on important hepatic function even
when the cells are viable. This suggests that employing cell viability as a sole marker for
effect of environment exposures including nanoparticles is a weak biomarker to identify
potential risk factors of these exposures.
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3.4 Conclusion
We treated primary rat hepatocytes with different types of TiO2 Nanoparticles in a range
of concentrations to determine the LC50 values that enabled us to select the sub-acute range
of 20, 50 and 100 µg/ml as the working concentrations for the cellular studies. Hepatocytes
did not exhibit marked changes in cellular phenotype and only a moderate loss in cellular
viability at chosen concentrations. We observed a nanoparticle type and concentration
dependent loss in urea synthesis and albumin synthesis in primary hepatocytes subjected
to treatment and this effect was most pronounced in P25 treatment groups, closely followed
by anatase. Rutile treatment resulted in the least loss in hepatocyte functions.
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Chapter 4 Mechanistic Aspects of Titanium Dioxide Mediated Toxicity
4.1 Introduction
4.1.1 Titanium Dioxide and Oxidative Stress
Numerous studies have demonstrated that metal oxide nanoparticle induced toxicity is
primarily mediated by increased ROS production.48, 49 A study on HepG2 cells show ROS
mediated DNA damage in the cells, upon treatment with TiO2 Nanoparticles.
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Several

studies also demonstrate ROS mediated inflammatory response in the animal models. 48 23
It is well established that, in excess, ROS species can lead to highly detrimental
macromolecular interaction that can further lead to cellular events such as inflammation,
mitochondrial damage, membrane disruption and lastly cell death.

51

Mitochondrial

function and ROS production are mutually dependent where excessive ROS production
leads to mitochondrial stress and stressed mitochondria, in turn, produce more ROS
species.
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Few studies provide evidence of impaired mitochondrial bioenergetics and

apoptotic cell degeneration after low-level exposure to TiO2. 23, 24
4.1.2 The Liver and Mitochondria
Hepatocytes constitute approximately 80% of the liver mass. These cells exhibit high
metabolic and bio-transforming activity that consequently imposes high energy
requirements. To meet these energy requirements, hepatocytes contain a high density of
mitochondria, distributed uniformly throughout the cell body.53, 54 Mitochondria act as the
vital source of energy in hepatocytes and also play a significant role in extensive oxidative
metabolism and normal functioning of the liver.55 Inherently, mitochondria have a highly
dynamic nature; they undergo continual fission and fusion processes which counterbalance
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each other, to alter the organelle morphology that enables the cell to meet its metabolic
requirements and cope with internal or external stress.56,

57

Three central players that

control the process of mitochondrial fission and fusion resulting in the unique structural
features, have been identified in mammals: (1) Mitofusins 1 and 2 (Mfn-1 and Mfn-2) ; for
outer-membrane fusion (2) OPA1; for inner membrane fusion and (3) Drp1 for inner and
outer membrane fission.57 In normal conditions, mitochondrial fusion enhances
mitochondrial integrity by allowing component sharing across the tubular network.
However, fusion of highly damaged mitochondria to the network could be detrimental,
since impaired mitochondria generate reactive oxygen species (ROS) that results in
significant cellular damage.55, 57

The concern about adverse health effects of low-level exposure to TiO2 is imperative to
address, particularly to analyze whether TiO2 exposure leading to liver degeneration by
impairing mitochondrial bioenergetics. There is a plethora of published literature on acute
TiO2 toxicity, however, the effect of TiO2 exposure on the hepatocyte mitochondria and its
implications on the liver remain to be investigated.
Recent studies demonstrate that several liver diseases, are related to the optimal function
of mitochondrial dynamics that leads to differential regulation of the fusion and fission
markers discussed above.58, 59 Mitochondrial oxidative damage has been demonstrated to
be a major factor in several liver disorders such as nonalcoholic steatohepatitis, Wilson’s
disease, early graft dysfunction after liver transplantation, alcohol induced liver disease,
non-alcoholic fatty liver disease, viral hepatitis, cholestasis and chronic hepatitis C.53, 60-64
The condition of oxidative stress results in the formation of damaging ROS due to continual
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leaking of electrons from the respiratory chain.52 Functional impairment of mitochondria,
due to oxidative stress, in hepatocytes is often accompanied by modification of
mitochondrial proteins, DNA and lipid peroxidation which may lead to mitochondrial
bioenergetics failure, that eventually leads to compromise in cellular functions and
subsequent necrotic or apoptotic cell death.52 Fission protein Drp 1 has been linked to cell
death in previous studies.65 Diminished OPA1 and Mfn (1 and 2) levels have been reported
in biological systems that are in diseased state.66 Apart from diseases, recent studies have
demonstrated that exposure to several engineered materials, including nanomaterials, leads
to structural and functional alterations in mitochondrial membranes.67, 68
In this study we investigated the perturbations in the liver behavior and mitochondrial
characteristics caused by exposure to TiO2 nanoparticles in order to broaden our
understanding on the molecular mechanisms of liver dysfunction induced by these highly
utilized nanoparticles. We used primary hepatocytes to investigate the concentration and
type dependent toxic effects of commercially available rutile, anatase and P25 TiO2
nanoparticles on mitochondrial dynamics and hepatic functions. The results of our study
indicate that TiO2 nanoparticles induce ROS production, cause mitochondrial damage in
hepatocytes and compromise normal liver function.
4.2 Materials and Methods

4.2.1 Reactive Oxygen Species (ROS) Quantification
Reactive Oxygen Species (ROS) production was quantified by a H2DCFDA based
fluorescence assay. Briefly, the cells were washed to remove traces of serum from the
culture media and were incubated with 10µM H2DCFDA [Life Technologies, NY] for a
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duration of 30 min at 37 ºC. After incubation, cells were gently washed and cells were
trypsinized using TRYPLE select [Life Technologies, NY] and suspended in PBS. The cell
suspension was transferred to a 96 well plate, which was read at excitation 528 nm and
emission 405 nm using a SLFA plate reader [Biotek, Winooski, VT]. Hydrogen Peroxide
treatment was used as a positive control and the untreated hepatocytes were used as the
experimental control to normalize the fluorescence intensity.
4.2.2 Gene Expression Studies

4.2.2.1 RNA and cDNA preparation

At each time point total RNA from primary hepatocytes was isolated using RNeasy Micro
Kit [Qiagen, Valenica, CA] according to the manufacturer’s instructions. Briefly, cells
were trypsinized, centrifuge pelleted, washed with PBS and lysed in RLT buffer with equal
volume 70% ethanol. The mix was then centrifuged in an RNeasy spin column, washed
and concentrated until the final RNA was released into RNase free water. The quality and
quantity was determined by ND-1000 spectrophotometer [NanoDrop Technologies
Wilmington, DE] and reverse transcribed using iScriptTM cDNA synthesis kit [Bio-Rad
Laboratories, CA] by following manufacturer’s instructions.
4.2.2.2 qPCR
Quantitative Real Time PCR was performed using SYBR Green Master Mix [Applied
Biosystems, Foster City, CA] in an epgradient S Mastercycler [Eppendorf, NY]. The
primers of interest were obtained from Integrated DNA Technologies [Coralville, IA] with
the following sequences: OPA-1 (Forward 5’- CCTGTGAAGTCTGCCAATCC -3' and
Reverse

5’-

CTGGAAGATGGTGATGGGTT

-3'),

Mfn1

(Forward

5’-
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TCGTGCTGGCAAAGAAGG-3’ and Reverse 5’-CGATCAAGTTCCGGGTTCC-3’).
GAPDH

(Forward

5’

ATGATTCTACCCACGGCAAG

3’

and

Reverse

5’

CTGGAAGATGGTGATGGGTT 3’) was used as the housekeeping gene. The ΔΔCT
method was utilized for analysis of each target gene with respect to the housekeeping gene.

4.2.3 Mitochondrial Morphology Imaging
Mitotracker FM, green stain [Life Technologies, NY] was used for the specific staining of
primary hepatocyte mitochondria. Live cells were washed with PBS and the dye was
diluted to a concentration of 100 nM in Fluorobrite DMEM [Life Technologies, NY] and
added to the cells. Cells were incubated at 37 ºC for 45 min and then washed extensively
and imaged using confocal microscopy (Olympus FV500 IX 81).

4.2.4 Statistical Analysis
The difference between the various experimental groups was analyzed by a one-way
analysis of variance (ANOVA) using the statistical analysis embedded in SigmaPlot
Software using Tukey test. Q tests were employed to identify outliers in the data subsets.
For statistical analysis of all data, p<0.05 was used as the threshold for significance.
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4.3 Results
4.3.1 Titanium Dioxide Nanoparticles and Oxidative Stress
We quantified the ROS production using CM-H2-DCFDA dye in order to measure the
increased oxidized status of the cells in response to nanoparticles exposure (Fig. 15). At
the concentrations of 20, 50 and 100 µg/ml, a type dependent increase in ROS production
was observed when primary hepatocytes were exposed to TiO2 nanoparticles. The exposure
of hepatocytes to 50 µg/ml of P25 and anatase resulted in relatively highest ROS
production while exposure of the same concentration of rutile demonstrated lesser ROS
production.

Figure 15. Characterizing the effect of nanoparticle treatment on primary hepatocyte
mitochondrial functions; Quantification of Reactive Oxygen Species produced by primary
hepatocytes using DCFDA based fluorescence assay after treatment with the different TiO2
nanoparticles for a duration of 72 h. Significant difference with respect to control is denoted as *
p value < 0.0001, # p value < 0.05
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4.3.2 Titanium Dioxide Nanoparticles and Mitochondrial Dynamics

To understand the effect of nanoparticle treatment on mitochondrial dynamics, we
investigated the relative gene expressions of OPA-1 and Mfn-1 markers associated with
mitochondrial fusion events (Fig. 16). OPA-1 and Mfn-1 gene expression levels were
significantly down-regulated in hepatocytes when exposed to 50 µg/ml P25 and anatase
with commercially used P25 having the highest effect. On the contrary, down-regulation
of these markers in rutile treatment group was not substantial.

Figure 16. Characterizing the effect of nanoparticle treatment on primary hepatocyte
mitochondrial functions; Relative gene expressions of mitochondrial fusion markers when
primary hepatocytes are treated with nanoparticles at a concentration of 50 µg/ml as analyzed
using qPCR with GAPDH as housekeeping gene. Significant difference with respect to control is
denoted as * p value < 0.001 and # p value < 0.05
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4.3.2 Titanium Dioxide Nanoparticles and Mitochondrial Morphology
To probe the effect of the nanoparticles on the mitochondrial morphology and integrity, we
imaged the mitochondria using the fluorescent stain Mitotracker FM (Fig. 17). The
untreated primary hepatocytes depicted the typical fiber-like morphology indicating a
healthy mitochondria. When hepatocytes were exposed to TiO2 nanoparticles, there was a
significant loss in the fiber-like morphology and presence of high levels of fragmentation
was also observed.
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Figure 17. Fluorescent imaging of the mitochondrial morphology in primary rat hepatocytes
after treatment with the different TiO2 nanoparticles at a concentration of 50ppm using
Mitotracker green FM. Scale 20 microns.
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4.4 Discussion
To determine the underlying mechanism that potentially causes the loss in hepatic
functions intracellular levels of ROS, a marker for oxidative stress, was measured in
primary hepatocytes exposed to TiO2 nanoparticles. Numerous studies have demonstrated
that metal oxide nanoparticle induced toxicity is primarily mediated by increased ROS
production.48, 49 Our study indicates that anatase and P25 treated samples exhibit increased
ROS production (Fig. 15). This higher production of ROS in P25 and anatase indicates that
primary hepatocytes are in a high stress environment.
In normal physiological conditions, mitochondrion is the main coordinator of ROS
production that is key to maintaining a state of redox homeostasis in the cells, thereby
protecting it from the damage of oxidative stress.51 When the ROS production is higher
than the normal range, it results in an elevated state of oxidative stress and the cell responds
by overworking the anti-oxidative pathways. Increase in ROS levels leads to DNA or
protein denaturation, mitochondrial damage, lipid peroxidation, metabolic disorders and
ultimately cell apoptosis.69-73 Several studies demonstrated that various environmental
stresses lead to increased ROS production in cells.74
Recent studies have emphasized the interrelationship of ROS and mitochondrial health,
with respect to metabolic disorders and manifestation of various diseased states.75
Excessive ROS causes mitochondrial dysregulation and comprises the mitochondrial
dynamics resulting in a cyclic response that leads to excessive production of ROS.
Mitochondria are extremely dynamic in nature and undergo continual fission and fusion
processes which counterbalance each other, to alter the morphology that enables the cell to
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meet its metabolic requirements and cope with internal or external stress. OPA1 and Mfn1 are markers known to be instrumental in regulating the fusion process in maintaining the
mitochondrial dynamics. We observe a significant down-regulation in the gene expression
levels of OPA1 and Mfn-1 in the 50 µg/ml treated hepatocytes, whereas, this downregulation was not observed in rutile samples. (Fig. 16) We also investigated the effect of
nanoparticle treatment on fission event by probing Drp1, but we do not see a prominent
change in the relative gene expression levels (data not shown). This indicates that the
normal cellular balance between the fusion and fission events in mitochondria are disrupted
by the nanoparticle treatment, through impairment in the fusion process. Mitochondrial
fusion is vital in maintaining the respiratory functions of the organelle and any interference
in this function can be detrimental to the bio-energetics, thereby causing a cascade of
damage in the cells.
Subsequently, we analyzed of the effect of the different nanoparticle treatment on primary
hepatocyte mitochondrial morphology, to visualize the effect of disrupted mitochondrial
dynamics. Fig. 17 displays that as compared to healthy untreated hepatocytes, the treated
cells have fragmented and swollen mitochondria. Hepatocytes possess a unique
mitochondrial organization wherein the mitochondria are spread throughout the cell body
unlike other cells where the mitochondria are concentrated around the cell nuclei and
concentration decreases radially. Loss in the typical fiber-like morphology and increase in
fragmentation is a strong indication of compromise in the mitochondria dynamics. This is
also in sync with our observation where OPA-1 and Mfn-1 were significantly downregulated in hepatocytes exposed to TiO2 nanoparticles. Defects in mitochondrial fusion
result in mitochondria that appear swollen and spherical, instead of fiber-like. Together,
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these results provide confirmative proof that exposure to TiO2 nanoparticles even at
concentration as low as 50 µg/ml results in significant mitochondrial damage by
interrupting the fusion-fission equilibrium and affecting the mitochondrial dynamics.76

4.5 Conclusion
We observe that Titanium Dioxide Nanoparticles lead to a state of Oxidative Stress due to
overproduction of Reactive Oxygen Species. ROS production was most upregulated in P25
treated samples, followed by anatase and then rutile. Mitochondrial fusion markers Opa1
and Mfn1 showed a downregulation in the gene expression, indicating towards the
disruption of mitochondrial dynamics, through loss in the fusion event. We stained the
mitochondrial fibers using Mitotracker and visualized that the nanoparticle treatment of
P25 and anatase resulted in abnormal mitochondrial morphology. These results collectively
suggest a state of oxidative stress and mitochondrial damage in primary hepatocytes when
treated with TiO2 Nanoparticles.

50

Chapter 5 Conclusions
Overall, we observed that exposure of primary rat hepatocytes to different types of
commercially available TiO2 nanoparticles cause toxicological effects in the cells. We note
a modest loss in cell viability. However, hepatic specific functions, urea and albumin
synthesis, are significantly compromised due to TiO2 nanoparticles exposure within 72 h
even at concentrations as low as 20 µg/ml. We observed an increase the amount of
intracellular ROS production when hepatocytes are exposed to TiO2 nanoparticles, which
is indicative of oxidative stress related damages. Finally, we observe that exposure to TiO2
nanoparticles results in significant mitochondrial damage as seen in the down-regulation
of OPA1 and Mfn-1, markers that is indicative of the fusion cycle that is key to maintaining
the mitochondrial dynamics. This decreased levels of Mfn-1 and OPA1 results in the
fragmented mitochondrial network in hepatocytes exposed to TiO2 nanoparticles and is a
strong indicator of the disruption of the mitochondrial dynamics. From these observations,
we propose that TiO2 nanoparticles induce cytotoxicity of hepatocytes by (1) downregulating the fusion process thus disrupting the mitochondrial dynamics, (2) inducing
damages to the mitochondrial morphology, (3) triggering oxidative stress mediated by an
increase in ROS production that is associated with loss of cell viability, and (4) inducing
loss in hepatic functions including urea and albumin (Fig. 18). Therefore, we propose that
TiO2 nanoparticles could potentially contribute to subsequent adverse health effects and
the development of liver diseases such as liver fibrosis.
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Figure 18. Schematic representation of the possible damaging role of TiO2 nanoparticles on
primary hepatocytes. We propose that TiO2 induces loss in hepatic functions on primary
hepatocytes through the induction of oxidative stress mediated by an increase of ROS production,
and significant mitochondria damage by down-regulating the fusion cycle in the mitochondrial
dynamics.
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Chapter 6 Future Studies
1. Detailed exploration of the biochemical pathways related to mitochondrial
respiration and mitochondrial stress mediated cell death pathways will aid in a
better understanding of the toxicity effects observed.
2. We also propose that mitochondrial stress has the potential to be used as an early
and sensitive marker for nanotoxicological studies and can also supplement studies
aimed at designing better therapeutic measures to combat nanomaterial and other
engineered materials toxicity.
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